Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
50mg |
|
||
Other Sizes |
|
ln Vitro |
(+)-PD 128907 is 100 times more selective than human (Ki=179 nM) and rat dopamine D2 receptor and 900 times more selective than [3H]spiroperone binding at the dopamine D3 receptor (Ki human=1.7 nM, rat=0.84 nM) [1][2].
|
---|---|
ln Vivo |
(+)-PD 128907 dialysate DA levels in D3 knockout mice were markedly decreased. For the wild-type and D3 knockout mice, the IC25 values were 61 nM and 1327 nM, respectively. When comparing mice lacking D3 receptors to wild-type dialysate DA levels, the ratio of IC25 values revealed that (+)-PD 128907 was 22-fold more powerful in lowering DA levels. In wild-type mice, dialysate DA is reduced in a dose-related manner by D3 agonists. All tested doses (0.03, 0.1, and 0.3 mg/kg) significantly suppressed dialysate DA, according to post hoc analysis. In the ventral striatum of wild-type and knockout mice, the IC25 values were 0.05 and 0.44 mg/kg, respectively, showing that systemically administered (+)-PD 128907 is 9 times more effective than D3 in decreasing dialysate DA. Eliminate rats. In both wild-type and D3 mutant mice, dialysate DA was markedly reduced by (+)-PD 128907 at dosages of 1 mg/kg or above [3].
|
References |
[1]. Collins GT, et al. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther. 2005 Jul;314(1):310-9.
[2]. Bristow LJ, et al. The behavioural and neurochemical profile of the putative dopamine D3 receptor agonist, (+)-PD 128907, in the rat. Neuropharmacology. 1996 Mar;35(3):285-94. [3]. Zapata A, et al. Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses. Neuropharmacology. 2001 Sep;41(3):351-9. |
Molecular Formula |
C14H19NO3
|
---|---|
Molecular Weight |
249.30556
|
CAS # |
300576-59-4
|
Related CAS # |
23594-64-9;300576-59-4 (HCl);
|
SMILES |
CCCN1[C@@]2([H])[C@@](OCC1)([H])C3=CC(O)=CC=C3OC2.Cl
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~20.83 mg/mL (~72.89 mM)
H2O : ~16.67 mg/mL (~58.33 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.0111 mL | 20.0554 mL | 40.1107 mL | |
5 mM | 0.8022 mL | 4.0111 mL | 8.0221 mL | |
10 mM | 0.4011 mL | 2.0055 mL | 4.0111 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.